MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2024-25)
- Udyam number
- UDYAM-MP-23-0018547
Market Cap
₹137 Cr
CHOKSILA · BSE
Share Price
₹195.00
-0.51% today
Revenue
₹46.01 Cr
FY 2025-26 · +10.1% YoY
EBITDA
₹12.18 Cr
Margin 26.5%
Net Profit
₹1.04 Cr
FY 2025-26 · -31.6% YoY
P/E (TTM)
72.8x
P/B 5.4x
ROE
4.2%
ROCE 9.1%
Debt / Equity
1.29
Interest cover 56.2x
About Choksi Laboratories Limited
Data last updated:
Choksi Laboratories Limited is a public limited company based in Indore, Madhya Pradesh, India. It operates in the pharma contract r and d segment of the pharmaceuticals sector. It was incorporated on 29 January 1993 and has been in existence for over 33 years.
The company is registered with the Registrar of Companies (ROC), Gwalior, under CIN L85195MP1993PLC007471. Its GSTIN is 23AABCC2523L1Z0 (Madhya Pradesh). The company holds 3 GST registrations, all of them active. It is a listed company as per MCA records. Its shares are listed on BSE: 526546.
The company has an authorised share capital of ₹15 Cr and a paid-up capital of ₹6.97 Cr. It was formerly known as Choksi Analytical Services Limited. It is led by directors including Sunil Kumar Choksi (Managing Director) and Himika Choksi (Whole-Time Director).
Its last annual general meeting (AGM) was held on 16 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 1 Near Tulsiyana Industrial Park, Indore, Madhya Pradesh.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹46.01 Cr, a growth of 10.1% compared to the previous year. For the same year it recorded a net profit of ₹1.04 Cr (net margin 2.3%) and EBITDA of ₹12.18 Cr (EBITDA margin 26.5%). The net worth stands at ₹25.58 Cr (up 8.3% YoY). Total assets are valued at ₹61.84 Cr (up 13.2% YoY).
The company has about 369 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Choksi Laboratories. As per MCA filings, the company has open charges of ₹34.16 Cr and satisfied charges of ₹49.89 Cr on record. Court records list 18 cases involving the company, including 12 filed by the company and 6 filed against it; 4 cases are pending. The company has 74 deals on record (74 market trades); the latest was in September 2026. The company has 11 MSME Form 1 returns on record between 2019 and 2024, listing 91 overdue payments to 16 micro and small suppliers.
Choksi Laboratories Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-MP-23-0018547). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website choksilab.com.
Company details
CIN L85195MP1993PLC007471
Registration Number 007471
Incorporation Date 29 January 1993
ROC Gwalior
Listing Status Listed - Listed on BSE (526546)
Company Status Active
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-MP-23-0018547
Key People
Sunil Kumar Choksi Managing Director Himika Choksi Whole-Time Director Vyangesh Choksi Whole-Time Director Recognitions & Rankings of Choksi Laboratories
Contact details
Choksi Laboratories Limited's registered office is in Indore, Madhya Pradesh. Its website is choksilab.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressSurvey No 9/1 Near Tulsiyana Industrial Park Gram Kum, Erdi, Indore, Madhya Pradesh, India – 452010
- IndustryPharma, Pharma Contract R&D
To see the full contact details of Choksi Laboratories Limited, buy the company report.
Comprehensive company report
Choksi Laboratories Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Choksi Laboratories operates one associated brand: Choksi Laboratories. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Laboratory services for pharmaceutical and food analysis are provided. | choksilab.com |
Business activity
The main business activity of Choksi Laboratories is professional, scientific and technical. In detail, this covers architecture, engineering activities, technical testing and analysis activities.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M4 | Architecture, engineering activities, technical testing and analysis activities |
To see the full business activity and turnover split of Choksi Laboratories Limited, buy the company report.
Financials of Choksi Laboratories Limited
FY 2025-26 filings availableChoksi Laboratories Limited reported revenue of ₹46.01 Cr (up 10.1% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue
₹46.01 Cr
+10.1% YoY
EBITDA
₹12.18 Cr
+7.8% YoY
Profit After Tax
₹1.04 Cr
-31.6% YoY
Net Worth
₹25.58 Cr
+8.3% YoY
Total Assets
₹61.84 Cr
+13.2% YoY
Total Debt
₹34.17 Cr
+17.2% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 46.01 | 41.78 | 36.70 | 34.44 | 30.04 | 25.69 | 28.16 |
| Revenue growth | +10.1% | +13.8% | +6.6% | +14.7% | +16.9% | -8.8% | - |
| EBITDA | 12.18 | 11.30 | 10.27 | 9.70 | 8.90 | 4.12 | 0.41 |
| EBITDA margin | +26.5% | +27.1% | +28.0% | +28.2% | +29.6% | +16.0% | +1.5% |
| Profit before tax | 3.20 | 2.15 | 1.66 | 3.72 | 0.36 | (2.81) | (5.71) |
| Net profit | 1.04 | 1.52 | 1.11 | 1.64 | 0.20 | (2.62) | (0.75) |
| Net profit margin | +2.3% | +3.6% | +3.0% | +4.8% | +0.7% | -10.2% | -2.7% |
| EPS (₹) | 2.82 | 2.19 | 1.59 | 4.61 | 0.30 | (3.74) | (5.58) |
| Balance sheet | |||||||
| Total assets | 61.84 | 54.65 | 54.90 | 55.05 | 56.58 | 57.96 | 54.82 |
| Net worth | 25.58 | 23.61 | 22.22 | 21.11 | 17.91 | 17.75 | 20.23 |
| Total debt | 34.17 | 29.15 | 30.87 | 32.41 | 37.29 | 39.15 | 31.64 |
| Cash & bank | 0.21 | 0.61 | 0.66 | 0.34 | 0.41 | 0.31 | 0.43 |
| Net working capital | 8.80 | 5.64 | 7.52 | 8.64 | 6.18 | 4.61 | 6.36 |
| Cash flow | |||||||
| Cash from operations | 7.86 | 11.78 | 11.55 | 8.25 | 7.88 | 5.90 | 2.87 |
| Cash from investing | (7.07) | (7.61) | (6.65) | (0.71) | (2.71) | (7.65) | (13.76) |
| Cash from financing | (1.20) | (4.22) | (4.58) | (7.61) | (5.07) | 1.63 | 11.09 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 12.06 | 12.82 | 10.82 | 11.12 | 11.24 | 11.40 | 10.38 | 9.26 |
| Revenue growth (YoY) | +7.3% | +12.5% | +4.2% | +20.1% | +4.7% | - | - | - |
| Other income | 0.02 | 0.06 | 0.89 | 0.01 | 0.00 | 0.04 | 0.01 | 0.01 |
| Total expenses | 8.78 | 9.18 | 8.17 | 8.19 | 8.34 | 7.90 | 7.84 | 6.90 |
| EBITDA | 3.28 | 3.64 | 2.65 | 2.93 | 2.90 | 3.50 | 2.54 | 2.36 |
| EBITDA margin | +27.2% | +28.4% | +24.5% | +26.3% | +25.8% | +30.7% | +24.5% | +25.5% |
| Depreciation | 1.97 | 1.89 | 1.83 | 1.69 | 1.68 | 1.70 | 1.68 | 1.61 |
| Interest | 0.73 | 0.71 | 0.81 | 0.69 | 0.60 | 0.58 | 0.69 | 0.66 |
| Profit before tax | 0.60 | 1.10 | 0.90 | 0.56 | 0.62 | 1.26 | 0.18 | 0.10 |
| Tax | 0.02 | 0.07 | 0.59 | 0.32 | 0.24 | 0.34 | 0.08 | 0.02 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 13 Nov 2026
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 12.06 | 12.82 | 10.82 | 11.12 | 11.24 | 11.40 | 10.38 | 9.26 |
| Revenue growth (YoY) | +7.3% | +12.5% | +4.2% | +20.1% | +4.7% | - | - | - |
| Other income | 0.02 | 0.06 | 0.89 | 0.01 | 0.00 | 0.04 | 0.01 | 0.01 |
| Total expenses | 8.78 | 9.18 | 8.17 | 8.19 | 8.34 | 7.90 | 7.84 | 6.90 |
| EBITDA | 3.28 | 3.64 | 2.65 | 2.93 | 2.90 | 3.50 | 2.54 | 2.36 |
| EBITDA margin | +27.2% | +28.4% | +24.5% | +26.3% | +25.8% | +30.7% | +24.5% | +25.5% |
| Depreciation | 1.97 | 1.89 | 1.83 | 1.69 | 1.68 | 1.70 | 1.68 | 1.61 |
| Interest | 0.73 | 0.71 | 0.81 | 0.69 | 0.60 | 0.58 | 0.69 | 0.66 |
| Profit before tax | 0.60 | 1.10 | 0.90 | 0.56 | 0.62 | 1.26 | 0.18 | 0.10 |
| Tax | 0.02 | 0.07 | 0.59 | 0.32 | 0.24 | 0.34 | 0.08 | 0.02 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 46.01 | 41.78 | 36.70 | 34.44 | 30.04 | 25.69 | 28.16 |
| Revenue growth | +10.1% | +13.8% | +6.6% | +14.7% | +16.9% | -8.8% | - |
| Other income | 0.97 | 0.07 | 0.16 | 3.04 | 0.12 | 0.49 | 0.33 |
| Total expenses | 33.83 | 30.48 | 26.43 | 24.74 | 21.14 | 21.57 | 27.75 |
| Employee cost | 16.62 | 15.22 | 13.03 | 12.00 | 11.04 | 10.78 | 11.70 |
| EBITDA | 12.18 | 11.30 | 10.27 | 9.70 | 8.90 | 4.12 | 0.41 |
| EBITDA margin | +26.5% | +27.1% | +28.0% | +28.2% | +29.6% | +16.0% | +1.5% |
| Depreciation | 7.09 | 6.50 | 5.71 | 5.50 | 5.43 | 4.60 | 4.56 |
| Interest | 2.86 | 2.72 | 3.06 | 3.52 | 3.23 | 2.82 | 1.89 |
| Profit before tax | 3.20 | 2.15 | 1.66 | 3.72 | 0.36 | (2.81) | (5.71) |
| Tax | 1.23 | 0.63 | 0.55 | 0.51 | 0.16 | (0.20) | (1.83) |
| Net profit | 1.04 | 1.52 | 1.11 | 1.64 | 0.20 | (2.62) | (0.75) |
| Net profit margin | +2.3% | +3.6% | +3.0% | +4.8% | +0.7% | -10.2% | -2.7% |
| EPS (₹) | 2.82 | 2.19 | 1.59 | 4.61 | 0.30 | (3.74) | (5.58) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 |
| Reserves & surplus | 18.61 | 16.64 | 15.25 | 14.14 | 10.94 | 10.78 | 13.26 |
| Shareholders' funds (net worth) | 25.58 | 23.61 | 22.22 | 21.11 | 17.91 | 17.75 | 20.23 |
| Secured loans | 27.83 | 28.07 | 29.27 | 30.35 | 33.77 | 35.14 | 30.36 |
| Unsecured loans | 6.34 | 1.08 | 1.60 | 2.06 | 3.52 | 4.01 | 1.28 |
| Total debt | 34.17 | 29.15 | 30.87 | 32.41 | 37.29 | 39.15 | 31.64 |
| Total liabilities | 61.84 | 54.65 | 54.90 | 55.05 | 56.58 | 57.96 | 54.82 |
| Assets | |||||||
| Gross block | 94.13 | 84.72 | 74.31 | 70.94 | 68.71 | 67.56 | 45.94 |
| Net block | 51.55 | 47.62 | 43.44 | 44.83 | 46.56 | 50.32 | 33.08 |
| Capital work in progress | 0.40 | 0.00 | 2.99 | 0.31 | 1.67 | 0.50 | 13.06 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.24 | 0.56 | 0.36 | 0.21 | 0.25 | 0.11 | 0.18 |
| Sundry debtors | 14.73 | 11.27 | 10.39 | 10.65 | 10.29 | 8.16 | 6.99 |
| Cash & bank balances | 0.21 | 0.61 | 0.66 | 0.34 | 0.41 | 0.31 | 0.43 |
| Loans & advances | 3.70 | 3.88 | 3.16 | 2.75 | 3.06 | 4.45 | 8.95 |
| Total current assets | 18.88 | 16.32 | 14.57 | 13.95 | 14.01 | 13.03 | 16.55 |
| Total current liabilities | 10.08 | 10.68 | 7.05 | 5.31 | 7.83 | 8.42 | 10.19 |
| Net working capital | 8.80 | 5.64 | 7.52 | 8.64 | 6.18 | 4.61 | 6.36 |
| Total assets | 61.84 | 54.65 | 54.90 | 55.05 | 56.58 | 57.96 | 54.82 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.61 | 0.66 | 0.34 | 0.41 | 0.31 | 0.43 | 0.23 |
| Net cash from operating activities | 7.86 | 11.78 | 11.55 | 8.25 | 7.88 | 5.90 | 2.87 |
| Net cash from investing activities | (7.07) | (7.61) | (6.65) | (0.71) | (2.71) | (7.65) | (13.76) |
| Net cash from financing activities | (1.20) | (4.22) | (4.58) | (7.61) | (5.07) | 1.63 | 11.09 |
| Net change in cash | (0.41) | (0.04) | 0.32 | (0.07) | 0.10 | (0.12) | 0.20 |
| Closing cash | 0.21 | 0.61 | 0.66 | 0.34 | 0.41 | 0.31 | 0.43 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +10.1% | +13.8% | +6.6% | +14.7% | +16.9% | -8.8% | - |
| EBITDA growth | +7.8% | +10.0% | +5.9% | +9.0% | +116.0% | +904.9% | - |
| PBT growth | +48.8% | +29.5% | -55.4% | +933.3% | +9998.0% | +50.8% | - |
| Net income growth | -31.6% | +36.9% | -32.3% | +720.0% | +107.6% | -249.3% | - |
| Revenue CAGR (3Y) | +10.1% | +11.6% | +12.6% | +6.9% | -3.8% | -5.5% | -0.7% |
| EBITDA CAGR (3Y) | +7.9% | +8.3% | +35.6% | +187.1% | +7.0% | -13.4% | -55.9% |
| Profitability & leverage | |||||||
| Net income margin | +4.3% | +3.6% | +3.0% | +9.3% | +0.7% | -10.2% | -13.8% |
| Return on capital employed | +9.1% | +8.9% | +8.6% | +8.9% | +6.3% | +0.0% | -1.4% |
| Return on net worth | +4.2% | +6.6% | +5.1% | +8.4% | +1.2% | -13.7% | -3.4% |
| Debt / equity | 1.29 | 1.31 | 1.46 | 1.79 | 2.14 | 1.86 | 1.10 |
| Long-term debt / equity | 0.75 | 0.76 | 1.02 | 1.45 | 1.79 | 1.59 | 0.95 |
| Interest cover | 56.19 | 56.67 | 67.11 | 83.81 | 93.08 | -587.50 | -45.54 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.51 | 0.53 | 0.51 | 0.49 | 0.44 | 0.45 | 0.62 |
| Inventory turnover | 115.03 | 90.83 | 128.77 | 149.74 | 166.89 | 177.17 | 95.46 |
| Debtors turnover | 3.54 | 3.86 | 3.49 | 3.29 | 3.26 | 3.39 | 3.57 |
| EPS (₹) | 2.82 | 2.19 | 1.59 | 4.61 | 0.30 | (3.74) | (5.58) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 36.72 | 33.89 | 31.89 | 30.31 | 25.70 | 25.48 | 29.03 |
To see the full year-wise statements and ratios of Choksi Laboratories Limited, buy the company report.
Board of directors of Choksi Laboratories Limited
Choksi Laboratories has 8 current directors and 12 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Himika Choksi Also directs: Corequal Systems LLP | Whole-Time Director | 01 Mar 2017 | 9 Years 8 Months | Current |
| Raghmendra Singh | Director | 13 Aug 2022 | 4 Years 3 Months | Current |
| Vyangesh Choksi | Whole-Time Director | 01 Aug 2009 | 17 Years 3 Months | Current |
| Sunil Kumar Choksi Also directs: Corequal Systems LLP | Managing Director | 01 Sep 2008 | 18 Years 2 Months | Current |
| Stela Choksi | Whole-Time Director | 01 Apr 2011 | 15 Years 7 Months | Current |
| Prachi Mantri | Director | 03 Feb 2024 | 2 Years 9 Months | Current |
Showing 6 of 8 current directors. View all directors
Auditor
Choksi Laboratories Limited is audited by Prateek Jain & Co for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Prateek Jain & Co | FY 2023 | 009494C |
Shareholding
Shareholding for the quarter ended Mar 2026: promoters hold 31.50%, foreign institutional investors hold 6.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 62.50%.
Mar 2026
QUARTER
31.50% Promoters
6.00% FII (Foreign Institutional)
62.50% Retail & Others
Promoter holding - history
Now 31.50% · Mar 2026High 31.50% · Jun 2025Low 31.50% · Jun 2025
Shareholding trend - last 6 quarters
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | |
|---|---|---|---|---|
| Promoters | 31.50% | 31.50% | 31.50% | 31.50% |
| Public | 68.50% | 68.50% | 68.50% | 68.50% |
Charges & borrowings
Open charges
₹34.16 Cr
Satisfied charges
₹49.89 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 19 May 2026 | 101303333 | Hdfc Bank Limited | ₹18.49 Lakh | Open | |
| 31 May 2025 | 101113240 | Hdfc Bank Limited | ₹12.5 Lakh | Open | |
| 23 Jan 2025 | 101052582 | State Bank of India | ₹6.75 Cr | Open | |
| 21 May 2024 | 100933492 | Hdfc Bank Limited | ₹50 Lakh | Open | |
| 10 Oct 2023 | 100790610 | State Bank of India | ₹68 Lakh | Open |
To see the full charge records of Choksi Laboratories Limited, buy the company report.
Total charge records: 39 View all charges
Deals & funding
Choksi Laboratories Limited has 74 deals on record (74 market trades); the latest was in September 2026.
Total deals
74
Market trades
74
Deals on record (5 of 74)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Aug 2026 | Market trade | ₹2.33 Cr | Buyer: Nexus Global Opportunities Fund Seller: Emkay Commercial Company Limited, Asc Consulting Private Limited |
| May 2026 | Market trade | ₹72.1 Lakh | Buyer: Nexus Global Opportunities Fund Seller: CSG Financial & Management Services Private Limited |
| Nov 2025 | Market trade | ₹57.6 Lakh | Seller: Essence Dealmark Private Limited |
| May 2025 | Market trade | ₹52.8 Lakh | Buyer: Alankit Imaginations Limited Seller: PSR Wealth Advisors LLP |
| May 2025 | Market trade | ₹1 Cr | Buyer: Alankit Imaginations Limited , Nexus Global Opportunities Fund, an individual Seller: an individual |
To see the full deal history of Choksi Laboratories Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Choksi Laboratories Limited has 18 court cases on record: 12 filed by Choksi Laboratories, 6 filed against it. 4 cases are pending and 14 are disposed.
Total cases
18
Filed by the company
12
Filed against the company
6
Pending
4
Disposed
14
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 17 | 5 | 4 |
| High courts | 1 | 1 | 0 |
Cases on record (5 of 18)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Indore, Madhya Pradesh | Court case (UN CR) | Filed by the company against an individual | Pending |
| District court, Indore, Madhya Pradesh | Court case (UN CR) | Filed by the company against an individual | Pending |
| District court, Yavatmal, Maharashtra | Court case (Cri.Rev.App.) | Filed against the company by Maharashtra State Through S.B. Datir, Drugs Inspector | Pending |
| District court, Indore, Madhya Pradesh | Court case (UN CR) | Filed by the company against an individual | Pending |
| High Court, ORISSA | Writ petition | Filed against the company by an individual | Disposed |
To see the full case history of Choksi Laboratories Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Choksi Laboratories Limited has 11 MSME Form 1 returns on record between 2019 and 2024, listing 91 overdue payments to 16 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 16)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| P.K.Carbonics P.Ltd | |||
| an individual supplier | |||
| an individual supplier | |||
| an individual supplier |
To see the full MSME payment records of Choksi Laboratories Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Choksi Laboratories Limited has a workforce of 369 employees on its EPFO records as of May 2026, across 4 active EPFO establishments.
Employee count
369
Active EPFO establishments
4
Employee growth
7.9%
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2026-27 | 369 |
| FY 2025-26 | |
| FY 2024-25 | |
| FY 2023-24 | |
| FY 2022-23 | |
| FY 2021-22 | |
| FY 2020-21 | |
| FY 2019-20 | |
| FY 2018-19 | |
| FY 2017-18 | |
| FY 2016-17 |
To see the full employee and EPFO history of Choksi Laboratories Limited, buy the company report.
GST
Choksi Laboratories has 3 GST registrations: 3 active.
Total GSTINs
3
Active
3
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 23AABCC2523L1Z0 | Madhya Pradesh | Active | 01 Jul 2017 |
| 06AABCC2523L1ZW | Haryana | Active | 01 Jul 2017 |
| 30AABCC2523L1Z5 | Goa | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Choksi Laboratories Limited, buy the company report.
Recent activity
Choksi Laboratories Limited has 27 board changes on record since 1999: 18 appointments and 9 cessations. The latest: Ritik Pavecha was appointed as Director on 07 Feb 2026.
Charges
A charge with State Bank Of India of Rs. 19.82 Cr registered on 19 Jun 2019 with Charge ID 100271142 was modified on 09 Jun 2026.
Charges
A charge registered on 29 Sep 2020 via Charge ID 100376418 with State Bank Of India was fully satisfied on 22 May 2026.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.18 Cr with Charge ID 101303333 was registered on 19 May 2026.
Filing
Choksi Laboratories Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Gwalior.
Appointed
Ritik Pavecha was appointed as Director.
AGM
Choksi Laboratories Limited last Annual general meeting of members was held on 16 Sep 2025 as per latest MCA records.
Charges
A charge registered on 29 Aug 2022 via Charge ID 100609368 with Canara Bank was fully satisfied on 29 Aug 2025.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.13 Cr with Charge ID 101113240 was registered on 31 May 2025.
Charges
A charge with State Bank Of India amounted to Rs. 6.75 Cr with Charge ID 101052582 was registered on 23 Jan 2025.
Charges
A charge with State Bank Of India of Rs. 2.37 Cr registered on 29 Sep 2020 with Charge ID 100376418 was modified on 08 Oct 2024.
Charges
A charge registered on 03 Sep 2021 via Charge ID 100483896 with Canara Bank was fully satisfied on 11 Sep 2024.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.50 Cr with Charge ID 100933492 was registered on 21 May 2024.
93 earlier events are in the company report.
News
Frequently asked questions
Choksi Laboratories is an active public limited company based in Indore, Madhya Pradesh, India. The company works in pharma contract r and d, within the pharma industry. It was incorporated on 29 January 1993 (33+ years old) and is registered under CIN L85195MP1993PLC007471. Listed on BSE: 526546.
Choksi Laboratories reported revenue of ₹46.01 Cr for FY 2025-26 (up 10.1% YoY) based on standalone financials.
Choksi Laboratories has 8 current directors:
- Sunil Kumar Choksi - Managing Director
- Himika Choksi - Whole-Time Director
- Vyangesh Choksi - Whole-Time Director
- Stela Choksi - Whole-Time Director
- Raghmendra Singh - Director
- Prachi Mantri - Director
- Abha Shastri - Director
- Ritik Pavecha - Director
The latest financial statements of Choksi Laboratories on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 16 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Choksi Laboratories is 23AABCC2523L1Z0, registered in Madhya Pradesh. The company has 3 GST registrations in all, of which 3 are active. Other active GSTINs include 06AABCC2523L1ZW (Haryana), 30AABCC2523L1Z5 (Goa).
The CIN (Corporate Identification Number) of Choksi Laboratories is L85195MP1993PLC007471. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Choksi Laboratories is a listed company as per MCA records. Its shares are listed on BSE (code: 526546).
Choksi Laboratories has 18 court cases on record: 12 filed by the company and 6 filed against it. 4 are pending. Most are in the district courts.
Choksi Laboratories was incorporated on 29 January 1993, making it 33+ years old. It is registered with the Registrar of Companies, Gwalior.
Choksi Laboratories has 74 deals on record (74 market trades); the latest was in September 2026.
Ritik Pavecha was appointed as Director on 07 Feb 2026. Abha Shastri was appointed as Director on 01 Apr 2024. Sudarshan Shastri ceased to be Director on 31 Mar 2024. Choksi Laboratories has 27 board changes on record in total.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages